Q-omics provides the consensus-scored MIR23A profile across patient tissues and cancer cell-line models. MIR23A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR23A is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, MIR23A RNA expression shows 15,277 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where MIR23A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR23A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR23A survival associations across molecular data types. MIR23A RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR23A RNA expression–survival associations across cancer types. High MIR23A expression shows unfavorable associations in ACC, UVM and THCA, but favorable associations in HNSC, STAD and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR23A RNA expression.
This table summarizes MIR23A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIR23A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR23A shows lower tumor expression in KICH, BRCA, LUAD, KIRP, BLCA and LUSC. The KICH box plot shows higher MIR23A RNA expression in normal versus tumor tissue (log2 FC = −2.472, t-test p < 0.001).
This table shows molecular features associated with MIR23A in patient tissues and cancer cell lines. In patient samples, MIR23A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
